Protective effect of vanillin in streptozotocin-induced diabetes in neonatal rats via attenuation of oxidative stress and inflammation

Abstract

Purpose: To evaluate the antidiabetic activity of vanillin in streptozotocin (STZ)-induced diabetic rats. Methods: Diabetes was induced in 2-day old male pups by intraperitoneal (i.p.) administration of STZ (90 mg/kg). The pups were then randomly assigned to four groups: control group which received citrate buffer only in place of STZ; negative control group, i.e., diabetic group; and vanillin-treated groups which received vanillin (100 or 200 mg/kg, p.o.) continuously from the 6th week of age to the 10th week. The antidiabetic effect of vanillin was determined by measuring the serum levels of insulin, triglycerides and glucose in the diabetic rats. Oral glucose tolerance, kidney and liver function tests were also performed at the end of the protocol. Moreover, the oxidative stress and inflammatory cytokines in liver tissues, and histopathological changes in pancreatic tissues were assessed. Results: Vanillin treatment significantly decreased serum glucose and triglyceride levels and increased the level of insulin, when compared to the negative control group. There was higher insulin sensitivity in the vanillin-treated group than in the negative control group. In addition, vanillin improved liver and renal functions in STZ-induced diabetic neonatal rats. Hepatic oxidative stress and inflammatory mediators, as well as histopathological changes in pancreas were attenuated by vanillin treatment. Conclusion: These results reveal that vanillin attenuates hyperglycemia in STZ-induced neonatal diabetic rat model by decreasing oxidative stress and inflammatory cytokines. There, further studies are required to develop the anti-diabetic potentials of vanillin for clinical applications.

HPLC-DAD phenolics screening and in vitro investigation of haemostatic, antidiabetic, antioxidant and photoprotective properties of Centaurea tougourensis Boiss. & Reut.

“…The antioxidant and anticancer properties of vanillin are well-known, but this compound has also non negligible anti-hyperglycaemic effect. Lu et al [63] showed that this compound can regulate the serum level of glucose and insulin in diabetic rats and even conserve the integrity of pancreas tissues. Another study carried out by Iannuzzi et al [64] proved that this compound could prevent diabetes complications by blocking glycation of insulin, precisely via a non-covalent binding process between vanillin and positively charged arginine 22 (Arg22) of insulin.…”

Naringenin and Vanillin Mitigate Cadmium-Induced Pancreatic Injury in Rats via Inhibition of JNK and p38 MAPK Pathways

“…12,13 It was reported in the literature that NGN and VLN significantly protected against streptozotocininduced pancreatic β-cell injury and diabetes mellitus. [14][15][16] In addition, NGN mitigated acute pancreatitis induced by caerulein and L-arginine in mice. 17 The current work was done to investigate the possible protective effects of NGN, VLN and NGN + VLN in a rat model of cadmium-induced pancreatic injury and to elucidate the feasible mechanisms mediating these protective effects.…”

Kisspeptin a potential therapeutic target in treatment of both metabolic and reproductive dysfunction

“…Similar to humans, in animal models of obesity, various dysfunctions are observed including raised body fat and triglyceride levels, glucose intolerance, and insulin resistance, which may lead (especially in extended exposure to HFD) to the development of T2D. A commonly used method to induce T2D in animals employs combination of feeding with HFD followed by injections of low doses of streptozotocin (a toxin that destroys the pancreas) 81 . Such animal models mimic the human condition, where T2D is often associated with obesity and a HFD.…”

“…A commonly used method to induce T2D in animals employs combination of feeding with HFD followed by injections of low doses of streptozotocin (a toxin that destroys the pancreas). 81 Such animal models mimic the human condition, where T2D is often associated with obesity and a HFD.…”